GlassScriptPhysician profile
Colleen H Patton
NPI 1902160930
$800.91
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $98.95 · 2022: $404 · 2023: $134 · 2024: $163.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $298.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $297.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $110.69 | 2021-2022 | |
| Janssen Biotech, INC. | $108.54 | 2022-2024 | Tecvayli, Darzalex, Talvey |
| Merck Sharp & Dohme LLC | $83.55 | 2022 | |
| Lilly USA, LLC | $60.50 | 2022 | |
| Novartis Pharmaceuticals Corporation | $49.70 | 2022 | |
| Masimo Corporation | $46.38 | 2022 | |
| Celgene Corporation | $39.60 | 2022-2024 | Reblozyl |
| Tempus Ai, INC | $38.16 | 2024 | Xt Cdx |
| E.R. Squibb & Sons, L.L.C. | $35.53 | 2022-2024 | Krazati |
| Mirati Therapeutics, INC. | $35.38 | 2023 | Krazati |
| Pfizer INC. | $26.38 | 2024 | |
| Astellas Pharma US INC | $25.58 | 2023 | Xospata |
| Amgen INC. | $23.68 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.31 | 2024 | Fruzaqla |
| Taiho Oncology, INC. | $19.11 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $17.50 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.50 | 2022 | |
| Incyte Corporation | $14.89 | 2022 | |
| Abbvie INC. | $14.58 | 2024 | |
| Glaxosmithkline, LLC. | $14.35 | 2023 | Shingrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Colleen Patton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.